ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RX Biosyent Inc

8.51
-0.14 (-1.62%)
06 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Biosyent Inc TSXV:RX TSX Venture Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.14 -1.62% 8.51 8.51 8.60 8.61 8.51 8.60 2,432 20:59:59

BioSyent to Present at Upcoming Investor Conference

24/08/2018 5:00pm

GlobeNewswire Inc.


Biosyent (TSXV:RX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Biosyent Charts.

BioSyent Inc. (“BioSyent”, “the Company”) (TSX Venture: RX) is pleased to announce that it will be presenting at the Midwest IDEAS Investor Conference at The Gwen in Chicago, Illinois. Mr.  René  Goehrum, BioSyent’s President  and  CEO, will present  to  investors  an overview  of  BioSyent’s business and  corporate  activities on Wednesday, August 29th at 9:20 a.m. ET. Mr. Goehrum will also be available for one-on-one meetings during the day on August 29th.  Interested investors can request meetings with Mr. Goehrum through the online conference platform: https://www.meetmax.com/sched/event_48313/entity_login.html?attendee_role_id=COMPANY. 

  About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.  BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.  

As of the date of this press release, the Company has 14,519,603 common shares issued and outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. GoehrumPresident and CEOBioSyent Inc.Tel: (905) 206-0013E-Mail: investors@biosyent.comWeb: www.biosyent.com

1 Year Biosyent Chart

1 Year Biosyent Chart

1 Month Biosyent Chart

1 Month Biosyent Chart

Your Recent History

Delayed Upgrade Clock